Diabetic kidney disease (chronic kidney disease) occurs when a person’s kidneys have been damaged due to complications from type 2 diabetes – a chronic condition that affects the way your body metabolizes sugar (glucose). Type 2 diabetes is a leading cause of diabetic kidney disease, also known as chronic kidney disease. Once the kidneys are damaged, they cannot filter the blood as well as they should, which oftentimes leads to the following symptoms:
- Weight gain
- Ankle and leg swelling
- Leg cramps
- High blood pressure
- Frequent urination, especially at night
- Increased excretion of protein in the urine
When diabetic kidney disease progresses beyond repair, a person experiences kidney failure. Currently, there are only two treatment options – a kidney transplant or dialysis. A kidney transplant is a surgical procedure that requires a donor whose kidney will be accepted by the recipient’s body. Dialysis is an artificial blood-cleaning process that uses a machine to filter waste from the blood. It generally requires multiple visits to a dialysis center each week for the remainder of a person’s life.
How the REACT Study aims to change all that
The therapy being tested in the REACT Study – Neo-Kidney Augment (NKA) cell therapy – could potentially become a new treatment option for people with diabetic kidney disease, with the possibility of preventing or delaying the need for dialysis or a kidney transplant. NKA cell therapy is a new, personalized treatment made from a small number of your own healthy kidney cells. NKA is made from your own cells, so there is no risk of rejection or an immune reaction like there can be with a donor kidney transplant.
If you have diabetic kidney disease and are not yet on dialysis, the REACT Study may be right for you. To see if you may qualify to participate, take the questionnaire now.
See If You May Qualify